News Sentiment

INVA sentiment intelligence

Innoviva Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 22.49 Week of 19 Jun 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-1.1% over one week, +0.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

H.C. Wainwright reiterates Innoviva stock rating on drug delivery platform By Investing.com

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -1.1% Price digesting
Trend fit Trend active 0.1% over four weeks
Fair value 25.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 34
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
simplywall.st 7
TradingKey 7
Stock Titan 6
Sahm 3
Business Wire 3
Stock Traders Daily 3
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 18
Deals and strategy 5
Analyst action 3
Guidance 3
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Sahm Direct company coverage

Will XACDURO Licensing Deal With Dr. Reddy’s Reshape Innoviva’s (INVA) Infectious Disease Strategy?

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., recently entered an exclusive distribution and licensing agreement with Dr. Reddy’s Laboratories for XACDURO® across various international regions. This deal helps expand XACDURO®'s global reach and offers Innoviva

Tone
Positive 62/100
Event
Deals and strategy
Published
19 Jun 2026 21:09
Source
Sahm
Business Wire Direct company coverage

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Nortiva Bio, a clinical-stage biopharmaceutical company and wholly-owned subsidiary of Innoviva, Inc., has officially launched to develop long-acting oral medicines. The company utilizes its proprietary LYNX™ drug delivery platform, which can transform daily pills into once-month

Tone
Positive 72/100
Event
Market update
Published
19 Jun 2026 08:39
Source
Business Wire
TradingKey Direct company coverage

Innoviva Inc (INVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Innoviva Inc (INVA), detailing its current earnings forecast score, average price target from analysts, and a breakdown of analyst ratings. It also includes expected revenue for the next quarter, past and future EPS performance, and

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 21:09
Source
TradingKey
Stock Titan Direct company coverage

Innoviva spins out Nortiva Bio to make pills last up to a month

Innoviva, Inc. has officially launched Nortiva Bio, a clinical-stage biopharmaceutical company focused on developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. This platform aims to transform daily pills into single-dose therapies lasting up to

Tone
Positive 73/100
Event
Market update
Published
18 Jun 2026 11:40
Source
Stock Titan
TradingKey Direct company coverage

Innoviva Inc (INVA) Financial Health: Profitability & Balance Sheet Analysis

Innoviva Inc (INVA) demonstrates robust financial health, ranking 22nd out of 157 in the Pharmaceuticals industry with a financial score of 8.98. The company reported a 10.56% year-over-year increase in quarterly revenue to $97.99 million and a significant 500.56% year-over-year

Tone
Positive 93/100
Event
Earnings
Published
18 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

Innoviva Inc (INVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Innoviva Inc (INVA), focusing on business segments and regional contributions. It notes that relevant data for recent fiscal quarters (FY2025Q1, Q2, Q4) and FY2024 has not yet been disclosed by the company. However, it does show a Uni

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 18:40
Source
TradingKey
TradingKey Direct company coverage

Innoviva Inc (INVA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Innoviva Inc's (INVA) historical dividend payouts and stock splits. It states that no dividend data is available for the past five years and no stock split data is found. The article also includes current stock performance metrics for INVA.

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 18:40
Source
TradingKey
TradingKey Direct company coverage

Innoviva Inc (INVA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Innoviva Inc (INVA), listing its major shareholders and their respective proportions. It also categorizes shareholders by type, such as investment advisors and hedge funds, and provides a historical overview of institutional share

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 18:11
Source
TradingKey
BioSpectrum India Direct company coverage

Innoviva Specialty Therapeutics inks distribution and licensing agreement with Dr. Reddy’s

Innoviva Specialty Therapeutics has partnered with Dr. Reddy’s Laboratories through an exclusive distribution and licensing agreement. This collaboration aims to develop and commercialize XACDURO® for the treatment of severe Acinetobacter baumannii-calcoaceticus complex infection

Tone
Positive 71/100
Event
Market update
Published
17 Jun 2026 11:11
Source
BioSpectrum India
Business Wire Direct company coverage

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO

Innoviva Specialty Therapeutics has partnered with Dr. Reddy’s Laboratories for the distribution and licensing of XACDURO in select international markets including South and Central America, the Caribbean, Russia, and CIS countries. This agreement aims to expand access to XACDURO

Tone
Positive 72/100
Event
Market update
Published
17 Jun 2026 08:39
Source
Business Wire
Stock Titan Direct company coverage

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Innoviva Specialty Therapeutics has partnered with Dr. Reddy's Laboratories to distribute and commercialize the pneumonia drug XACDURO in Latin America, the Caribbean, Russia, and CIS countries. This agreement aims to expand access to XACDURO, an antibiotic for hospital-acquired

Tone
Positive 66/100
Event
Market update
Published
17 Jun 2026 07:40
Source
Stock Titan
grafa.com Direct company coverage

Innoviva partners with Dr. Reddy's for XACDURO licensing

Innoviva Specialty Therapeutics has entered an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for its antibiotic XACDURO. Dr. Reddy's will handle the development and commercialization of the drug in South America, Central America, the Caribbean, and

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 14:09
Source
grafa.com
Investing.com Direct company coverage

Innoviva unit signs distribution deal with Dr. Reddy’s

Innoviva Specialty Therapeutics has signed an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd. for its antibiotic XACDURO in South and Central America, the Caribbean, Russia, and CIS countries. Innoviva Inc. (NASDAQ:INVA) is set to receive an upfr

Tone
Positive 72/100
Event
Deals and strategy
Published
16 Jun 2026 13:10
Source
Investing.com
Stock Traders Daily Direct company coverage

Responsive Playbooks and the INVA Inflection

This article analyzes Innoviva Inc. (NASDAQ: INVA) with a neutral near and mid-term outlook but a positive long-term bias. It highlights a strong risk-reward short setup and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, eac

Tone
Neutral 50/100
Event
Guidance
Published
16 Jun 2026 03:38
Source
Stock Traders Daily
Quartr Direct company coverage

Innoviva (INVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 Summary

Innoviva (INVA) presented at the 47th Annual Goldman Sachs Global Healthcare Conference, highlighting its diversified business model comprising resilient royalty streams, a rapidly growing specialty therapeutics business (IST), and strategic healthcare assets. The company emphasi

Tone
Positive 74/100
Event
Market update
Published
09 Jun 2026 19:09
Source
Quartr
Stock Traders Daily Direct company coverage

Understanding the Setup: (INVA) and Scalable Risk

This article analyzes Innoviva Inc. (NASDAQ: INVA), highlighting divergent sentiment across different time horizons, suggesting choppy market conditions. It identifies a mid-channel oscillation pattern and outlines three distinct AI-generated trading strategies—Position Trading,

Tone
Negative 38/100
Event
Market update
Published
05 Jun 2026 02:08
Source
Stock Traders Daily
New Castle News Direct company coverage

Innoviva to Participate in Upcoming Investor Conferences

Innoviva, Inc., a diversified biopharmaceutical company, announced its participation in two upcoming investor conferences in June 2026. Management will attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th and the BTIG Infectious Disease Day on June 16th.

Tone
Positive 61/100
Event
Market update
Published
03 Jun 2026 04:10
Source
New Castle News
Sahm Direct company coverage

Innoviva Board Shift And New Treatment Launch Create Valuation Question

Innoviva (NasdaqGS:INVA) has appointed Josephine Linden to its Board following two director resignations related to Syndeio BioSciences, a company Innoviva supports. Concurrently, Innoviva is preparing to launch a newly approved gonorrhea treatment. These developments, set agains

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 14:38
Source
Sahm
geneonline.com Direct company coverage

Innoviva, Inc. to Present at Investor Conferences

Innoviva, Inc. announced its participation in upcoming investor conferences, where its management team will present business and strategic insights. These presentations offer a platform for Innoviva to discuss its financial performance, ongoing projects, and future outlook with b

Tone
Positive 63/100
Event
Guidance
Published
02 Jun 2026 03:09
Source
geneonline.com
GuruFocus Direct company coverage

INVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $46

HC Wainwright & Co. has reiterated a "Buy" rating for Innoviva (INVA), maintaining a price target of $46.00, despite the stock being 5.7% overvalued according to GuruFocus's GF Value™. Innoviva, which operates in the biotechnology industry, has a strong GF Score™ of 90/100, indic

Tone
Positive 66/100
Event
Analyst action
Published
01 Jun 2026 12:39
Source
GuruFocus
Kavout Direct company coverage

Has Innoviva Successfully Pivoted Beyond its Royalty Roots

Innoviva (INVA) is successfully transforming from a royalty-dependent company into a diversified biopharmaceutical entity with a strong Q4 2025 earnings beat driven by its Specialty Therapeutics platform and robust sales of XacDuro in China. The company's strategic pivot includes

Tone
Positive 73/100
Event
Earnings
Published
30 May 2026 01:09
Source
Kavout
GuruFocus Direct company coverage

INVA Reiterates by BTIG -- Price Target Maintained at $42

BTIG analyst Julian Harrison has reiterated a "Buy" rating for Innoviva (INVA), maintaining a price target of $42.00, despite the stock currently trading at $22.46, indicating it is 10.9% overvalued according to GuruFocus's GF Value™. Innoviva, a biopharmaceutical company with a

Tone
Positive 60/100
Event
Analyst action
Published
26 May 2026 22:12
Source
GuruFocus